← Back to Clinical Trials
Recruiting NCT06624826

NCT06624826 Visual Performance of an Extended Depth of Focus IOL in an Emmetropic or Monovision Modality

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06624826
Status Recruiting
Phase
Sponsor Prim. Prof. Dr. Oliver Findl, MBA
Condition Cataract
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2024-10-01
Primary Completion 2025-10-01

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age 105 Years
Study Type INTERVENTIONAL
Interventions
Emmetropic modalityMonovision modality

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2024-10-01 with a primary completion date of 2025-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Comparison of the visual performance of a refractive extended depth of focus intraocular lens in an emmetropic or monovision modality

Eligibility Criteria

Inclusion Criteria: * Age-related bilateral cataract * Age 21 or older * Visual acuity \> 0.05 * Axial length: 21.00-27.00mm * Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically relevant * Written informed consent prior to surgery Exclusion Criteria: * Active ocular disease (e.g chronic uveitis, diabetic retinopathy, chronic glaucoma not responsive to medication, corneal dystrophies, etc.) precluding good post-operative visual acuity * Relevant other ophthalmic diseases such as pseudoexfoliation syndrome (PEX) * Irregular astigmatism on corneal tomography * Pronounced dry eye disease * Previous ocular surgery or trauma * Persons who are pregnant or nursing (pregnancy test will be taken in women of reproductive age)

Contact & Investigator

Central Contact

Johannes Zeilinger, MD

✉ office@viros.at

📞 01 91021 57564

Principal Investigator

Oliver Findl, Prim. Prof. Dr.

PRINCIPAL INVESTIGATOR

Vienna Institute for Research in Ocular Surgery (VIROS)

Frequently Asked Questions

Who can join the NCT06624826 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, up to 105 Years, studying Cataract. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06624826 currently recruiting?

Yes, NCT06624826 is actively recruiting participants. Contact the research team at office@viros.at for enrollment information.

Where is the NCT06624826 trial being conducted?

This trial is being conducted at Vienna, Austria.

Who is sponsoring the NCT06624826 clinical trial?

NCT06624826 is sponsored by Prim. Prof. Dr. Oliver Findl, MBA. The principal investigator is Oliver Findl, Prim. Prof. Dr. at Vienna Institute for Research in Ocular Surgery (VIROS). The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology